Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesA population-based clinical trial of irinotecan and carboplatin
Journal of Oncology, 06/15/09
Lau D et al. – Study demonstrates that the population-based design of phase I trial allows optimization of dose intensity and derivation of a population-based maximum tolerated dose (pMTD). The pMTD has been applied in phase II trial of irinotecan and carboplatin in patients with small-cell lung cancer.
Methods- Study describes a population-based design for phase I trials of combining anticancer drugs such as irinotecan and carboplatin
- Intrapatient dose escalation of irinotecan and carboplatin was performed to reach individual dose-limiting toxicity (DLT)
- 50 pts with solid tumors refractory to previous chemotherapy
- The individual toxicity-limiting dose levels were analyzed for normal distribution using the method of Ryan-Joiner
- This was subsequently used to determine a pMTD
- For comparison, a simulation study was performed using the method of modified Fibonacci
- Most common DLTs: neutropenia (58%), thrombocytopenia (16%), and diarrhea (8%)
- Fequency of individual toxicity-limiting dose levels of 50 pts approximated a normal distribution
- Dose levels associated with individual limiting toxicities ranged from level 1 to level 8
- pMTD was determined to be dose level 3 (150mg/m2 for irinotecan and AUC=5 for carboplatin)
- In contrast, the MTD was determined to be dose level 4 (200mg/m2 for irinotecan and AUC 5 for carboplatin) by modified-Fibonacci simulation
Related Articles
A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic NSCLC
Annals of Oncology, 10/19/09
Relevance Score: 90%
Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors
European Journal of Cancer, 10/23/09
Relevance Score: 89%
DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells
BMC Cancer, 10/15/09
Relevance Score: 89%
Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck
Annals of Oncology, 11/10/09
Relevance Score: 88%
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer unfit for cisplatin-based chemotherapy: Phase II--results of EORTC Study 30986
Journal of Clinical Oncology, 10/05/09
Relevance Score: 87%
Today in Drug Interactions...keeping you current
Receive free subspecialty "5-minute updates" via email
Semi-Mechanistic Population Pharmacokinetic Drug-Drug Interaction Modelling of a Long Half-Life Substrate and Itraconazole
Clinical Pharmacokinetics, 12/18/09
Acetazolamide and midazolam act synergistically to inhibit neuropathic pain
Pain, 12/16/09
Cyclosporine Versus Tacrolimus in Immunosuppressive Maintenance Regimens in Renal Transplants in Brazil: Survival Analysis from 2000 to 2004
Annals of Pharmacotherapy, 12/16/09
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09
ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09
Milatuzumab – a promising new immunotherapeutic agent
Expert Opinion on Investigational Drugs, 12/17/09
Sponsor
Article Search
Sponsor
Sponsor